Related Experiment Video

Updated: Jul 15, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Cetuximab rescue a patient with non-small cell lung cancer from rapid disease progression during chemotherapy

Sang Joon Shin, Hye Won Lee, Se Hyun Kim

    Acta Oncologica (Stockholm, Sweden)
    |May 15, 2007
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
    09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    Related Experiment Videos

    Last Updated: Jul 15, 2026

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
    09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD.

    Clinical lung cancer·2026

    Amivantamab plus chemotherapy vs. chemotherapy in participants with EGFR-mutant advanced non-small cell lung cancer after progression on osimertinib: a MARIPOSA-2 analysis of the Asian subgroup.

    Translational lung cancer research·2026

    Evaluation of MET Detection Methods and Cutoffs in EGFR-Mutated Non-small Cell Lung Cancer Following Disease Progression on Osimertinib in the phase II SAVANNAH study.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Patient-reported outcomes with tarlatamab in extensive-stage small cell lung cancer after platinum-based chemotherapy: results from the phase 3 DeLLphi-304 trial.

    Lung cancer (Amsterdam, Netherlands)·2026

    Structural basis and preclinical efficacy of MG1124, a novel CEACAM1-targeting antibody synergizing with PD-1 blockade.

    Molecular cancer therapeutics·2026

    Rilvegostomig for Metastatic Non-Small Cell Lung Cancer: A First-In-Human Phase I/II Clinical Study.

    Clinical cancer research : an official journal of the American Association for Cancer Research·2026

    Treatment attrition and outcomes of myeloma patients in Finland: a real-world study.

    Acta oncologica (Stockholm, Sweden)·2026

    Detection of circulating tumor HPV-DNA in patients with HPV-positive sinonasal and nasopharyngeal carcinoma.

    Acta oncologica (Stockholm, Sweden)·2026

    Continuous intrathecal therapy for refractory cancer pain: A systematic review and meta-analysis focusing on partially implanted devices.

    Acta oncologica (Stockholm, Sweden)·2026

    Co-mutation patterns and survival associations in lung cancer: a comparative analysis of Swedish and global cohorts.

    Acta oncologica (Stockholm, Sweden)·2026

    Tools for providing information to patients about high-tech medical resources for treatment of cancer.

    Acta oncologica (Stockholm, Sweden)·2026

    Primary treatment and relative survival by stage and age in vaginal carcinoma: a population-based SweGCG study.

    Acta oncologica (Stockholm, Sweden)·2026

    Advances in the LI-RADS Treatment Response Algorithm: Imaging Principles, Diagnostic Challenges, and Clinical Integration Following the LI-RADS 2024 Update.

    Cancer management and research·2026

    Prevention and management of hormonal crisis in neuroendocrine tumors undergoing PRRT (peptide receptor radionuclide therapy): a systematic review.

    ESMO gastrointestinal oncology·2026

    Timing of cranial radiotherapy in HER2-positive breast Cancer brain metastases treated with Pyrotinib: a multicentre real-world cohort study.

    Clinical and translational radiation oncology·2026

    A HALF CENTURY OF PROGRESS IN BREAST CANCER: WHERE DO WE GO NEXT?

    Transactions of the American Clinical and Climatological Association·2026

    Engineering exosomes-mediated RNA delivery regulates bone homeostasis and alleviates osteoporosis.

    Materials today. Bio·2026

    EMSCs-derived exosomes rescue p75NTR-/- -mediated osteogenesis deficiency via PI3K/Akt/ERK1/2 signaling pathways.

    Materials today. Bio·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us